Adverse Outcome Pathway-Driven Analysis of Liver Steatosis in Vitro: A Case Study with Cyproconazole
Open Access
- 11 July 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 31 (8), 784-798
- https://doi.org/10.1021/acs.chemrestox.8b00112
Abstract
Adverse outcome pathways (AOPs) describe causal relationships between molecular perturbation and adverse cellular effects and are being increasingly adopted for linking in vitro mechanistic toxicology to in vivo data from regulatory toxicity studies. In this work, a case study was performed by developing a bioassay toolbox to assess key events in the recently proposed AOP for chemically induced liver steatosis. The toolbox is comprised of in vitro assays to measure nuclear receptor activation, gene and protein expression, lipid accumulation, mitochondrial respiration, and formation of fatty liver cells. Assay evaluation was performed in human HepaRG hepatocarcinoma cells exposed to the model compound cyproconazole, a fungicide inducing steatosis in rodents. Cyproconazole dose-dependently activated RARα and PXR, two molecular initiating events in the steatosis AOP. Moreover, cyproconazole provoked a disruption of mitochondrial functions and induced triglyceride accumulation and the formation of fatty liver cells as described in the AOP. Gene and protein expression analysis, however, showed expression changes different from those proposed in the AOP, thus suggesting that the current version of the AOP might not fully reflect the complex mechanisms linking nuclear receptor activation and liver steatosis. Our study shows that cyproconazole induces steatosis in human liver cells in vitro and demonstrates the utility of systems-based approaches in the mechanistic assessment of molecular and cellular key events in an AOP. AOP-driven in vitro testing as demonstrated can further improve existing AOPs, provide insight regarding molecular mechanisms of toxicity, and inform predictive risk assessment.Keywords
Funding Information
- H2020 Food (633172)
This publication has 55 references indexed in Scilit:
- Clinical epidemiology and disease burden of nonalcoholic fatty liver diseaseWorld Journal of Gastroenterology, 2017
- Adverse Outcome Pathways--Organizing Toxicological Information to Improve Decision MakingThe Journal of pharmacology and experimental therapeutics, 2015
- Adverse Outcome Pathways and Drug-Induced Liver Injury TestingChemical Research in Toxicology, 2015
- Adverse Outcome Pathway (AOP) Development I: Strategies and PrinciplesToxicological Sciences, 2014
- Liver X receptors in lipid metabolism: opportunities for drug discoveryNature Reviews Drug Discovery, 2014
- Hepatic steatosis: A major trap in liver imagingDiagnostic and Interventional Imaging, 2013
- High-Content Imaging Technology for the Evaluation of Drug-Induced Steatosis Using a Multiparametric Cell-Based AssaySLAS Discovery, 2012
- Drug-induced toxicity on mitochondria and lipid metabolism: Mechanistic diversity and deleterious consequences for the liverJournal of Hepatology, 2011
- Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessmentEnvironmental Toxicology and Chemistry, 2009
- Lipid Metabolism and Liver Inflammation. II. Fatty liver disease and fatty acid oxidationAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2006